The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the ...

Among biotechnology stocks, several names have hovered around the top momentum percentile this week, signaling robust bullish activity and potential for short-term gains. Being close to the top 10 ...